Amarin (AMRN)
(Delayed Data from NSDQ)
$0.58 USD
+0.01 (2.32%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $0.58 0.00 (-0.55%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 81 - 100 ( 367 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Europe Can Present Second Wind for Vascepa, Despite Program?s Infancy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Applications for Vascepa; Reiterate Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Optimism in European Opportunity, While Generics Enter the Fray; PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Patent Appeal Hearing Does Not Inspire Confidence
Provider: Oppenheimer & Co. Inc.
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Prospects for CAFC Reversal Dampened - Outperform Rating Remains Intact
Provider: Northland Capital Markets
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Following Affirmation of Patent Invalidation, Focus is on the EU Vascepa Opportunity
Provider: Piper Sandler
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Panel Affirms Ruling Invalidating Vascepa IP In The US; Focus Shifts To EU But Surprised Mgmt Not Looking To Cut Costs Now
Provider: Stifel Nicolaus Co., Inc.
Analyst: Research Department